Metsera, Inc. (MTSR): Total Asset Value of Company

Graphic logo of Metsera Corp (MTSR)

Metsera Inc (MTSR) is developing long-acting peptide anti-obesity treatments to ensure stable earnings protected by patents. The company's aggregate resources on the GURU.Markets time chart confirm this foundation, where 0.00 determines the latest valuation metric. However, geopolitical tensions are slowing global trials and biomaterial deliveries while production facilities undergo scheduled modernization to meet international quality standards.

Metsera Inc (MTSR) Company Total Assets: for the period 02/01/2025 - 11/29/2025

Comprehensive metric breakdowns and analytics for Metsera Corp (MTSR)

- price and consensus price forecast:
Price Performance Chart metsera.com|MTSR - Price Target Chart
- market capitalization data:
Market Valuation Metsera Therapeutics|MTSR - Enterprise Value
- book capitalization data:
Accounting Value of a Share Metsera|MTSR - Book Capitalization|Market Capitalization to Book Value Ratio metsera.com|MTSR - Aggregate Company Assets
- debt and liquidity data:
All Debt to Shareholders' Equity Ratio Metsera Inc|MTSR - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Metsera Therapeutics|MTSR - Company Aggregate Debts|Debts to Book Capitalization Metsera Therapeutics
Fundamental valuation:MTSR, metsera.com
Finished products of Metsera Inc

Metsera Inc (MTSR) leverages the strong scientific expertise of its leadership to expand within the metabolic drug segment. Asset dynamics (equity + liabilities), reverse-calculated via ROA, reflect the total volume of resources and leverage, allowing investors to assess capital management efficiency and the pace of material base expansion to execute the long-term development strategy of the biotech portfolio.

Competitors of Metsera Inc (MTSR)

ASND (ascendispharma.com) - Aggregate Asset Value|Aggregate Company Assets Madrigal Pharmaceuticals, Inc. MDGL|Total Asset Value of Company Corcept Therapeutics Inc.|Rhythm Pharmaceuticals Inc (RYTM) - Company Total Assets|Aggregate Asset Value Akero Corp (AKRO)|Company Total Assets MLTX (MoonLake Immunotherapeutics)|crinetics.com - Company Total Assets|Aggregate Company Assets NewAmsterdam Pharma Company N.V. (NAMS)|SLNO: Aggregate Asset Value|FOLD (Amicus Pharma) - Aggregate Company Assets|89bio Pharma (ETNB) - Cumulative Company Assets|AGIO (Agios Pharmaceuticals) - Company Total Assets|Company Total Assets structuretx.com (GPCR)|MiMedx (MDXG) - Cumulative Company Assets|Aggregate Asset Value RZLT (Rezolute Inc)|Lexicon Pharma - Aggregate Company Assets|Cumulative Company Assets MBX Corp MBX|ALT (Altimmune, Inc.) - Company Total Assets|aardvarktherapeutics.com (AARD) - Company Assets|SGMT - Cumulative Company Assets|BioAge Labs (BIOA) - Aggregate Business Assets|BMEA (Biomea) - Company Total Assets|Company Total Assets Quince|Company Total Assets Fractyl Health, Inc. (GUTS)|Aggregate Company Assets VTVT (vtvtherapeutics.com)|ATPC: Aggregate Company Assets|Pluristem Therapeutics - Company Assets|SYBX - Aggregate Company Assets|LPCN - Aggregate Company Assets|matinasbiopharma.com - Company Total Assets|SPRB (sprucebiosciences.com) - Company Total Asset Base|GLTO: Aggregate Company Assets|Company Total Asset Base CTCX|Aggregate Company Assets LUMO (Lumos Pharma Corp)|Cumulative Company Assets ONVO (Organovo Corp)|Radius Recycling, Inc. - Aggregate Company Assets